Comparison · NCT02418312-5cc355fb
Histamine-2 Receptor Antagonist Group vs Placebo Group: Number of Participants With Healed Peptic Ulcer
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Histamine-2 Receptor Antagonist Group vs Placebo Group: Number of Participants With Healed Peptic Ulcer. Trial comparisons, record NCT02418312-5cc355fb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02418312-5cc355fb
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.93 | 0.868 | 0.964 | wilson | |
| Risk in group 2 | 0.886 | 0.815 | 0.932 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0439 | -0.0336 | 0.123 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.05 | 0.966 | 1.14 | log | |
| Odds ratio, group 1 over group 2 | 1.71 | 0.678 | 4.29 | log | |
| Number needed to treat, for one more participant with the outcome on Histamine-2 Receptor Antagonist Group than on Placebo Group | 22.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Histamine-2 Receptor Antagonist Group | famotidine 40mg qd for 6 months.~histamine-2 receptor antagonist: famotidine 40 mg qd plus thienopyridine | 106 | 114 | OG000 |
| Group 2 | Placebo Group | placebo for 6 months.~Placebo: placebo plus thienopyridine | 101 | 114 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Healed Peptic Ulcer
- Description
- Follow-up endoscopy was performed at the end of the 6th month
- Time frame
- 6 months
- Population
- Intention to treat
Source ClinicalTrials.gov
Trial
- Title
- Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer
- NCT number
- NCT02418312
- Phases
- NA
- Conditions
- Peptic Ulcer
- Interventions
- histamine-2 receptor antagonist, Placebo
- Lead sponsor
- Kaohsiung Veterans General Hospital.
- Results first posted
- 2019-03-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02418312?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02418312-5cc355fb